Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Chronic Renal Failure

  Free Subscription


Articles published in Curr Opin Nephrol Hypertens

Retrieve available abstracts of 40 articles:
HTML format
Text format



Single Articles


    January 2019
  1. GORAYA N, Wesson DE
    Clinical evidence that treatment of metabolic acidosis slows the progression of chronic kidney disease.
    Curr Opin Nephrol Hypertens. 2019 Jan 23. doi: 10.1097/MNH.0000000000000491.
    PubMed     Text format     Abstract available


  2. WALD R, Thorpe KE, Walsh MW
    Leveraging pragmatic clinical trial design to advance phosphate management in end-stage renal disease.
    Curr Opin Nephrol Hypertens. 2019;28:34-39.
    PubMed     Text format     Abstract available


    December 2018
  3. ARMSTRONG ME, Thomas CP
    Diagnosis of monogenic chronic kidney diseases.
    Curr Opin Nephrol Hypertens. 2018 Dec 28. doi: 10.1097/MNH.0000000000000486.
    PubMed     Text format     Abstract available


  4. GOLDFARB DS
    Controversies in kidney stones and other chronic kidney disease topics.
    Curr Opin Nephrol Hypertens. 2018 Dec 24. doi: 10.1097/MNH.0000000000000485.
    PubMed     Text format    


  5. SHAH R, Sparks MA
    Renin-angiotensin system inhibition in advanced chronic kidney disease: how low can the kidney function go?
    Curr Opin Nephrol Hypertens. 2018 Dec 24. doi: 10.1097/MNH.0000000000000484.
    PubMed     Text format     Abstract available


  6. SRIPERUMBUDURI S, Hiremath S
    The case for cautious consumption: NSAIDs in chronic kidney disease.
    Curr Opin Nephrol Hypertens. 2018 Dec 5. doi: 10.1097/MNH.0000000000000473.
    PubMed     Text format     Abstract available


    November 2018
  7. NG JK, Li PK
    Fluid management and bioimpedance study in peritoneal dialysis.
    Curr Opin Nephrol Hypertens. 2018 Nov 16. doi: 10.1097/MNH.0000000000000466.
    PubMed     Text format     Abstract available


  8. FRIEDMAN DJ
    Genes and environment in chronic kidney disease hotspots.
    Curr Opin Nephrol Hypertens. 2018 Nov 16. doi: 10.1097/MNH.0000000000000470.
    PubMed     Text format     Abstract available


  9. BURTON JO, Graham-Brown MPM
    Nocturnal hemodialysis: an underutilized modality?
    Curr Opin Nephrol Hypertens. 2018;27:472-477.
    PubMed     Text format     Abstract available


  10. PASUPULATI AK, Menon RK
    Growth hormone and chronic kidney disease.
    Curr Opin Nephrol Hypertens. 2018 Nov 1. doi: 10.1097/MNH.0000000000000468.
    PubMed     Text format     Abstract available


    October 2018
  11. VALDIVIELSO JM, Jacobs-Cacha C, Soler MJ
    Sex hormones and their influence on chronic kidney disease.
    Curr Opin Nephrol Hypertens. 2018 Oct 12. doi: 10.1097/MNH.0000000000000463.
    PubMed     Text format     Abstract available


  12. HANSSEN NMJ, Stehouwer CDA, Schalkwijk CG
    Methylglyoxal stress, the glyoxalase system, and diabetic chronic kidney disease.
    Curr Opin Nephrol Hypertens. 2018 Oct 12. doi: 10.1097/MNH.0000000000000465.
    PubMed     Text format     Abstract available


    September 2018
  13. BEAUBIEN-SOULIGNY W, Bouchard J, Denault A
    Point-of-care ultrasound in end-stage kidney disease: beyond lung ultrasound.
    Curr Opin Nephrol Hypertens. 2018 Sep 3. doi: 10.1097/MNH.0000000000000453.
    PubMed     Text format     Abstract available


  14. HASEGAWA S, Tanaka T, Nangaku M
    Hypoxia-inducible factor stabilizers for treating anemia of chronic kidney disease.
    Curr Opin Nephrol Hypertens. 2018;27:331-338.
    PubMed     Text format     Abstract available


    August 2018
  15. KALIM S
    Protein carbamylation in end stage renal disease: is there a mortality effect?
    Curr Opin Nephrol Hypertens. 2018 Aug 24. doi: 10.1097/MNH.0000000000000454.
    PubMed     Text format     Abstract available


  16. NIANG A, Iyengar A, Luyckx VA
    Hemodialysis versus peritoneal dialysis in resource-limited settings.
    Curr Opin Nephrol Hypertens. 2018 Aug 24. doi: 10.1097/MNH.0000000000000455.
    PubMed     Text format     Abstract available


  17. PONCE D, Brabo AM, Balbi AL
    Urgent start peritoneal dialysis.
    Curr Opin Nephrol Hypertens. 2018 Aug 22. doi: 10.1097/MNH.0000000000000451.
    PubMed     Text format     Abstract available


    July 2018
  18. TABINOR M, Davies SJ
    The use of bioimpedance spectroscopy to guide fluid management in patients receiving dialysis.
    Curr Opin Nephrol Hypertens. 2018 Jul 30. doi: 10.1097/MNH.0000000000000445.
    PubMed     Text format     Abstract available


  19. KALRA PA, Burlacu A, Ferro CJ, Covic A, et al
    Which anticoagulants should be used for stroke prevention in non-valvular atrial fibrillation and severe chronic kidney disease?
    Curr Opin Nephrol Hypertens. 2018 Jul 16. doi: 10.1097/MNH.0000000000000443.
    PubMed     Text format     Abstract available


  20. ERBEN RG
    alpha-Klotho's effects on mineral homeostasis are fibroblast growth factor-23 dependent.
    Curr Opin Nephrol Hypertens. 2018;27:229-235.
    PubMed     Text format     Abstract available


    June 2018
  21. ALI S, Dave N, Navaneethan SD
    Emerging therapeutic options for management of anaemia in with patients with chronic kidney disease.
    Curr Opin Nephrol Hypertens. 2018 Jun 22. doi: 10.1097/MNH.0000000000000434.
    PubMed     Text format    


  22. MACDOUGALL IC
    Iron therapy for managing anaemia in chronic kidney disease.
    Curr Opin Nephrol Hypertens. 2018 Jun 13. doi: 10.1097/MNH.0000000000000436.
    PubMed     Text format     Abstract available


    May 2018
  23. JELKMANN W
    Activin receptor ligand traps in chronic kidney disease.
    Curr Opin Nephrol Hypertens. 2018 May 29. doi: 10.1097/MNH.0000000000000433.
    PubMed     Text format     Abstract available


  24. DUBIN RF
    Application of echocardiographic data in patients with chronic kidney disease.
    Curr Opin Nephrol Hypertens. 2018 May 16. doi: 10.1097/MNH.0000000000000419.
    PubMed     Text format     Abstract available


  25. GUPTA N, Wish JB
    Erythropoietin mimetic peptides and erythropoietin fusion proteins for treating anemia of chronic kidney disease.
    Curr Opin Nephrol Hypertens. 2018 May 4. doi: 10.1097/MNH.0000000000000430.
    PubMed     Text format     Abstract available


  26. DEKKER MJE, Kooman JP
    Fluid status assessment in hemodialysis patients and the association with outcome: review of recent literature.
    Curr Opin Nephrol Hypertens. 2018;27:188-193.
    PubMed     Text format     Abstract available


    April 2018
  27. STRAUSSER SA, Nakano D, Souma T
    Acute kidney injury to chronic kidney disease transition: insufficient cellular stress response.
    Curr Opin Nephrol Hypertens. 2018 Apr 26. doi: 10.1097/MNH.0000000000000424.
    PubMed     Text format     Abstract available


  28. MOE SM
    Rationale to reduce calcium intake in adult patients with chronic kidney disease.
    Curr Opin Nephrol Hypertens. 2018 Apr 26. doi: 10.1097/MNH.0000000000000416.
    PubMed     Text format     Abstract available


  29. SCIALLA JJ
    Evidence basis for integrated management of mineral metabolism in patients with end-stage renal disease.
    Curr Opin Nephrol Hypertens. 2018 Apr 6. doi: 10.1097/MNH.0000000000000417.
    PubMed     Text format     Abstract available


    March 2018
  30. STELLER WAGNER MARTINS C, Jorgetti V, Moyses RMA
    Time to rethink the use of bone biopsy to prevent fractures in patients with chronic kidney disease.
    Curr Opin Nephrol Hypertens. 2018 Mar 31. doi: 10.1097/MNH.0000000000000418.
    PubMed     Text format     Abstract available


  31. ASHLEY J, Sood MM
    Novel oral anticoagulants in chronic kidney disease: ready for prime time?
    Curr Opin Nephrol Hypertens. 2018 Mar 22. doi: 10.1097/MNH.0000000000000410.
    PubMed     Text format     Abstract available


  32. CONNELLY K, Collister D, Tangri N
    Fracture risk and treatment in chronic kidney disease.
    Curr Opin Nephrol Hypertens. 2018 Mar 15. doi: 10.1097/MNH.0000000000000411.
    PubMed     Text format     Abstract available


    February 2018
  33. LI T, Xie Y, Al-Aly Z
    The association of proton pump inhibitors and chronic kidney disease: cause or confounding?
    Curr Opin Nephrol Hypertens. 2018 Feb 9. doi: 10.1097/MNH.0000000000000406.
    PubMed     Text format     Abstract available


    January 2018
  34. HAAS M
    Evolving criteria for the diagnosis of antibody-mediated rejection in renal allografts.
    Curr Opin Nephrol Hypertens. 2018 Jan 2. doi: 10.1097/MNH.0000000000000398.
    PubMed     Text format     Abstract available


    December 2017
  35. RAO M, Jaber BL, Balakrishnan VS
    Chronic kidney disease and acquired mitochondrial myopathy.
    Curr Opin Nephrol Hypertens. 2017 Dec 20. doi: 10.1097/MNH.0000000000000393.
    PubMed     Text format     Abstract available


    November 2017
  36. KRAUT JA, Madias NE
    Retarding progression of chronic kidney disease: use of modalities that counter acid retention.
    Curr Opin Nephrol Hypertens. 2017 Nov 14. doi: 10.1097/MNH.0000000000000386.
    PubMed     Text format     Abstract available


  37. SCHMIDT RJ
    Incorporating supportive care into the hemodialysis unit.
    Curr Opin Nephrol Hypertens. 2017;26:530-536.
    PubMed     Text format     Abstract available


    October 2017
  38. WALTHER CP, Chandra A, Navaneethan SD
    Blood pressure parameters and morbid and mortal outcomes in nondialysis-dependent chronic kidney disease.
    Curr Opin Nephrol Hypertens. 2017 Oct 16. doi: 10.1097/MNH.0000000000000375.
    PubMed     Text format     Abstract available


    September 2017
  39. GOLPER TA
    Incremental dialysis: review of recent literature.
    Curr Opin Nephrol Hypertens. 2017 Sep 11. doi: 10.1097/MNH.0000000000000362.
    PubMed     Text format     Abstract available


  40. SY J, Johansen KL
    The impact of frailty on outcomes in dialysis.
    Curr Opin Nephrol Hypertens. 2017 Sep 9. doi: 10.1097/MNH.0000000000000364.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Chronic Renal Failure is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: